Surgery and imatinib therapy for liver oligometastasis of GIST: a study of Japanese Study Group on GIST.

Autor:	Kanda T; Department of Surgery, Sanjo General Hospital, Sanjo, Japan., Masuzawa T; Department of Surgery, Osaka Police Hospital, Osaka, Japan., Hirai T; Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan., Ikawa O; Department of Surgery, Kyoto Second Red Cross Hospital, Kyoto, Japan., Takagane A; Department of Gastrointestinal Surgery, Hakodate Goryoukaku Hospital, Hakodate, Japan., Hata Y; Department of Radiology, Kochi Health Sciences Center, Kochi, Japan., Ojima H; Department of Surgery, Gunma Prefectural Cancer Center, Ota, Japan., Sodeyama H; Department of Surgery, Nagano Red Cross Hospital, Nagano, Japan., Mochizuki I; Department of Surgery, Iwate Prefectural Central Hospital, Morioka, Japan., Ishikawa T; Department of Medical Informatics, Niigata University Medical and Dental Hospital, Niigata, Japan., Kagimura T; Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, Kobe, Japan., Nishida T; National Cancer Center Hospital, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Japanese journal of clinical oncology [Jpn J Clin Oncol] 2017 Apr 01; Vol. 47 (4), pp. 369-372.
DOI:	10.1093/jjco/hyw203
Abstrakt:	We conducted a multicenter prospective study to clarify the efficacy and safety of surgery and imatinib for liver oligometastasis of gastrointestinal stromal tumors. Eligible gastrointestinal stromal tumor patients were enrolled in the surgery trial or the imatinib trial. Primary endpoints were recurrence-free survival and progression-free survival, respectively. The trials were prematurely terminated due to amendment of guidelines for adjuvant imatinib therapy and low patient accrual. In the surgery trial, all the six patients showed hepatic recurrence: median recurrence-free survival was 145 days (range: 62-1366 days). Of the five patients receiving salvage imatinib therapy, two showed progressive disease although no death was observed. Of the five patients enrolled in the imatinib trial, one died of pneumonia after progressive disease, and four had not shown progressive disease as of last visit. The results suggest that liver oligometastasis of gastrointestinal stromal tumor may not be controllable by surgery alone and require concomitant imatinib therapy. (© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu